Early Vigabatrin

Phase 2Small molecule

MMartina Bebin

Early Vigabatrin is one of 16 small molecule programs targeting Tuberous Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tuberous SclerosisActive, not recruiting

Tuberous SclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Tuberous Sclerosis

#DrugCompanyPhaseTrials

Afinitor

Novartis

Approved

8 2

Epidiolex

Jazz Pharmaceuticals

Approved

1 3

Rapamune

PPrism Pharmaceuticals

Approved

2 4

Fintepla

IImmedica Pharma AB

Approved

—5

Rocaltrol

Alnylam Pharmaceuticals

Phase 3

1 6

Sabril

Lundbeck

Phase 3

1 7

GWP42003-P

Jazz Pharmaceuticals

Phase 3

2 8

RAD001

Novartis

Phase 3

2 9

Rapamycin

MMaastricht Radiation Oncology

Phase 3

4 10

Bayer Aspirin

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tuberous Sclerosis1 trial

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

Completed·MMartina Bebin·Phase 2·NCT02849457·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Early Vigabatrin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Early Vigabatrin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Early Vigabatrin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Martina Bebin company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMartina Bebin

Early Vigabatrin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tuberous Sclerosis1 trial

References

Drug Info

Quick Facts

Related News